AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • September 28th, 2017 • Relmada Therapeutics, Inc. • Pharmaceutical preparations
This Agreement amends and restates in its entirety that certain Office Space License Agreement, dated as of March 10, 2016 and effective as of January 1, 2016, between Relmada and Actinium (the “Original Agreement”) for office space within the Premises. This Agreement is intended to and does completely amend and restate the Original Agreement.
ContractAssignment and Consent Agreement • September 28th, 2017 • Relmada Therapeutics, Inc. • Pharmaceutical preparations
THIS ASSIGNMENT AND CONSENT AGREEMENT (this “Agreement”), made as of the 6th day of June, 2017, between 275 MADISON AVENUE RPW 1 LLC and 275 MADISON AVENUE RPW 2 LLC, having an office in care of RPW Group, Inc., 800 Westchester Avenue, Rye Brook, New York 10573, hereinafter referred to collectively as the “Owner,” RELMADA THREAPEUTICS, INC., having an office at 275 Madison Avenue, Suite 702, New York, New York 10016, hereinafter referred to as the “Assignor,” and ACTINIUM PHARMACEUTICALS, INC., having an office at 275 Madison Avenue, Suite 702, New York, New York 10016, hereinafter referred to as the “Assignee.”
AGREEMENTAgreement • September 28th, 2017 • Relmada Therapeutics, Inc. • Pharmaceutical preparations • Pennsylvania
This AGREEMENT, effective February 15, 2017 (“EFFECTIVE DATE”) is made by and between MDB Communications LLC, 41 University Drive, Suite 400-01, Newtown, PA 18940 (“CONSULTANT”), and Relmada Therapeutics, Inc., 275 Madison Ave, STE 702, New York, NY, 10016 (“CLIENT”).
AGREEMENTAgreement • September 28th, 2017 • Relmada Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Agreement (“Agreement”) is entered into by and between Sandesh Seth (“Director” or “you”) and Relmada Therapeutics, Inc. (the “Company” or “Relmada”), and confirms the agreement that has been reached with you in connection with your resignation as a director of the Company (together, the “Parties”).
CONSULTING AGREEMENTConsulting Agreement • September 28th, 2017 • Relmada Therapeutics, Inc. • Pharmaceutical preparations
This Consulting Agreement (“Agreement”) is entered into on June 12, 2017 (the “Effective Date”) by and between Relmada Therapeutics, Inc., a Nevada corporation with a business address at 275 Madison Avenue, Suite 702, New York, NY 10016, U.S.A. (“Relmada” or the “Company”), and Maged Shenouda (“Consultant”).
ContractRelmada Therapeutics, Inc. • September 28th, 2017 • Pharmaceutical preparations • Tokyo
